Objectives: To assess the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and effects on serum concentrations of lipoprotein(a). Design, Setting, and Participants: Single- and multiple-dose study in healthy participant...
A Single and Multiple Ascending Dose Study of Toll‐Like Receptor 7 Agonist (RO7020531) in Chinese Healthy VolunteersToll‐like receptor 7 (TLR7)‐specific agonistChina Phase IPharmacokineticsPharmacodynamicsTLR7 agonists modulate broad spectrum immune activity and are evaluated in the treatment of human...
Phase 1 Single and Multiple Ascending Dose Study of CAT-2003, a Novel Activator of Lipoprotein Lipase, Decreases Postprandial Tr risk of requiring revascularization in this population. Priordata on this subject have been conflicting, and no similarstudies exist among patients treated with optimal medic...
Inc.onbehalf of The American College ofClinical PharmacologyDOI:10.1002/cpdd.720A First-in-Human Phase 1 RandomizedSingle and Multiple Ascending DoseStudy of RPh201 in Healthy VolunteersZadik Hazan 1 ,Konstantin Adamsky 1 ,Andre Lucassen 1 ,and Leonard A.Levin 2AbstractRPh201 is a drug extracte...
The objectives of these studies were to evaluate zilurgisertib pharmacokinetics, safety, tolerability, and the effect of food in healthy participants from phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies. Methods Both the SAD and MAD studies were double-blind, ...
A Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5382A Administered Orally,Pharmaxis,Interventional,Phase 1
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the ... A first-in-human randomized, double-blind, placebo-con- trolled, single- and multiple-ascending oral dose study of novel antimalarial...
METHODS. A phase 1 study was conducted to evaluate the safety and pharmacokinetics of PC786 delivered in a suspension formulation by nebulizer (PARI LC SPRINT device). Healthy volunteers (HVs) received placebo or PC786 as single ascending doses (0.5–20 mg, Cohort (C) 1), 5 mg BD for ...
SAFETY, TOLERABILITY, AND PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF PF-06751979, A POTENT AND SELECTIVE ORAL BACE1 INHIBITOR: RESULTS FROM PHASE1 SINGLE AND MULTIPLE ASCENDING DOSE STUDIES IN HEALTHY YOUNG AND OLDER VOLUNTEERS Author links open overlay panelRuolun Qiu 1, Richann Liu 1, Ping ...
of 2 to 3 hours post-dose, a plasma half-life of 17.4 to 21.5 hours and dose proportional increases in Cmax(maximum plasma drug concentration) and AUC (area under the concentration-time curve). “The unblinded data from the single and multiple ascending dose parts of our ...